Brief: Vicore Pharma Selects Systemic Sclerosis As Second Indication For Its Lead Program

Vicore Pharma Holding AB

23/04/2019 07:34

April 23 (Reuters) - Vicore Pharma Holding AB  VICOR.ST :
    * VICORE PHARMA - HAS SELECTED DIFFUSE SYSTEMIC SCLEROSIS
(DSSC)
AS SECOND INDICATION FOR ITS LEAD PROGRAM VP01 (C21)
    * VICORE PHARMA  - BOTH PHASE IIA STUDIES, IN IPF AND SELECT
PATIENTS WITH DSSC RESPECTIVELY, ARE EXPECTED TO COMMENCE IN
SECOND HALF OF 2019

Source text for Eikon:  ID:nWkr7fvfx4 
Further company coverage:  VICOR.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))